Latest news with #OraSureTechnologies
CNA
a day ago
- Business
- CNA
OraSure Technologies received takeover bid from industry entrepreneur, sources say
NEW YORK :Prominent healthcare entrepreneur Ron Zwanziger approached medical device maker OraSure Technologies with a takeover offer, three people familiar with the matter said, in what would mark more consolidation in the heavily fragmented diagnostic industry. In June, Zwanziger submitted an unsolicited all-cash proposal to buy the Bethlehem, Pennsylvania-headquartered company, known for its COVID-19 rapid antigen tests, the sources said. Along with a prominent Wall Street investor and others - people the sources did not identify - Zwanziger proposed paying between $3.50 and $4.00 a share for OraSure. OraSure's stock was trading aT $3.18 on Monday morning, leaving it with a market capitalization of $238.6 million. The company's board rejected the offer not long after it was sent, without any discussions between the parties, the three sources said. A company representative did not immediately respond to a request for comment. A representative for Zwanziger, a serial deal maker who cemented his reputation through at-home blood glucose testing, could not be reached for comment. Zwanziger has built and sold a handful of diagnostic companies during his long career, and sold diagnostic test manufacturer Alere Abbott Laboratories in 2017 for around $5.3 billion. The rebuffed offer for OraSure was his second effort to combine with the company, according to one of the sources. In 2022, only a few months after the company named Carrie Eglinton Manner as its chief executive officer, Zwanziger proposed a merger through a stock swap, but terms could not be reached, the source said. OraSure appealed to Zwanziger because of its solid core technology and he thought he could turn around the company's fortunes quickly with a new team, the sources said. The company's stock price has fallen 27 per cent in the last 12 months and is off 77 per cent over the last five years. Quarterly revenue has been dropping since early 2023 as COVID-19 era sales dried up. OraSure has been attempting to diversify its business as a result, buying Sherlock Biosciences late last year for its molecular diagnostics platform. Point of care diagnostic companies offer accurate results in real time to measure cholesterol, and detect flu and pregnancy, for example. But the industry still remains highly fragmented with companies such as Danaher, Siemens, Roche and Thermo Fisher Scientific capturing the biggest market share.
Reuters
a day ago
- Business
- Reuters
OraSure Technologies received takeover bid from industry entrepreneur, sources say
NEW YORK, July 14 (Reuters) - Prominent healthcare entrepreneur Ron Zwanziger approached medical device maker OraSure Technologies (OSUR.O), opens new tab with a takeover offer, three people familiar with the matter said, in what would mark more consolidation in the heavily fragmented diagnostic industry. In June, Zwanziger submitted an unsolicited all-cash proposal to buy the Bethlehem, Pennsylvania-headquartered company, known for its COVID-19 rapid antigen tests, the sources said. Along with a prominent Wall Street investor and others -- people the sources did not identify -- Zwanziger proposed paying between $3.50 and $4.00 a share for OraSure. OraSure's stock was trading aT $3.18 on Monday morning, leaving it with a market capitalization of $238.6 million. The company's board rejected the offer not long after it was sent, without any discussions between the parties, the three sources said. A company representative did not immediately respond to a request for comment. A representative for Zwanziger, a serial deal maker who cemented his reputation through at-home blood glucose testing, could not be reached for comment. Zwanziger has built and sold a handful of diagnostic companies during his long career, and sold diagnostic test manufacturer Alere Abbott Laboratories (ABT.N), opens new tab in 2017 for around $5.3 billion. The rebuffed offer for OraSure was his second effort to combine with the company, according to one of the sources. In 2022, only a few months after the company named Carrie Eglinton Manner as its chief executive officer, Zwanziger proposed a merger through a stock swap, but terms could not be reached, the source said. OraSure appealed to Zwanziger because of its solid core technology and he thought he could turn around the company's fortunes quickly with a new team, the sources said. The company's stock price has fallen 27% in the last 12 months and is off 77% over the last five years. Quarterly revenue has been dropping since early 2023 as COVID-19 era sales dried up. OraSure has been attempting to diversify its business as a result, buying Sherlock Biosciences late last year for its molecular diagnostics platform. Point of care diagnostic companies offer accurate results in real time to measure cholesterol, and detect flu and pregnancy, for example. But the industry still remains highly fragmented with companies such as Danaher (DHR.N), opens new tab, Siemens ( opens new tab, Roche (ROG.S), opens new tab and Thermo Fisher Scientific (TMO.N), opens new tab capturing the biggest market share.
Yahoo
a day ago
- Business
- Yahoo
OraSure Technologies received takeover bid from industry entrepreneur, sources say
By Svea Herbst-Bayliss NEW YORK (Reuters) -Prominent healthcare entrepreneur Ron Zwanziger approached medical device maker OraSure Technologies with a takeover offer, three people familiar with the matter said, in what would mark more consolidation in the heavily fragmented diagnostic industry. In June, Zwanziger submitted an unsolicited all-cash proposal to buy the Bethlehem, Pennsylvania-headquartered company, known for its COVID-19 rapid antigen tests, the sources said. Along with a prominent Wall Street investor and others -- people the sources did not identify -- Zwanziger proposed paying between $3.50 and $4.00 a share for OraSure. OraSure's stock was trading aT $3.18 on Monday morning, leaving it with a market capitalization of $238.6 million. The company's board rejected the offer not long after it was sent, without any discussions between the parties, the three sources said. A company representative did not immediately respond to a request for comment. A representative for Zwanziger, a serial deal maker who cemented his reputation through at-home blood glucose testing, could not be reached for comment. Zwanziger has built and sold a handful of diagnostic companies during his long career, and sold diagnostic test manufacturer Alere Abbott Laboratories in 2017 for around $5.3 billion. The rebuffed offer for OraSure was his second effort to combine with the company, according to one of the sources. In 2022, only a few months after the company named Carrie Eglinton Manner as its chief executive officer, Zwanziger proposed a merger through a stock swap, but terms could not be reached, the source said. OraSure appealed to Zwanziger because of its solid core technology and he thought he could turn around the company's fortunes quickly with a new team, the sources said. The company's stock price has fallen 27% in the last 12 months and is off 77% over the last five years. Quarterly revenue has been dropping since early 2023 as COVID-19 era sales dried up. OraSure has been attempting to diversify its business as a result, buying Sherlock Biosciences late last year for its molecular diagnostics platform. Point of care diagnostic companies offer accurate results in real time to measure cholesterol, and detect flu and pregnancy, for example. But the industry still remains highly fragmented with companies such as Danaher, Siemens, Roche and Thermo Fisher Scientific capturing the biggest market share. Sign in to access your portfolio
Yahoo
5 days ago
- Business
- Yahoo
OraSure Launches Novel Blood Collection Device for Proteomic Research
The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for research BETHLEHEM, Pa., July 10, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ('OTI') (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the launch of its HEMAcollect™●PROTEIN product to meet the evolving needs of proteomic researchers. The product, developed by OTI subsidiary DNA Genotek, is an evacuated blood collection tube (BCT) designed to preserve and stabilize plasma proteins in whole blood for up to seven days.* Currently available for research use only**, the collection tube with its proprietary stabilizing liquid preserves plasma proteins, facilitating storage and transport of blood samples at ambient temperature, which are limitations of general blood collection tubes. It is anticipated that the use of the product for sample collection will deliver operational and financial efficiencies to proteomic researchers and support the generation of high-quality data. "The HEMAcollect™●PROTEIN BCT represents a significant advancement in sample collection for proteomics, providing researchers with a reliable solution that preserves sample integrity and improves preanalytical workflows," said Carrie Eglinton Manner, President and CEO of OTI. "We're dedicated to enhancing the quality of insights for researchers through our innovative sample management solutions. The launch of this solution for blood proteomics applications is a clear reflection of that commitment and enables research applications in oncology, neurology, cardiology, metabolic disorders, and beyond.' The HEMAcollect™●PROTEIN BCT, powered by ProteoPrecision™ technology, minimizes hemolysis and activation of platelets, ensuring the sample accurately reflects the body's state at collection. It is compatible with a broad range of proteomic technologies including mass spectrometry, immunoassays, and high-throughput affinity-based platforms. For more information, visit About OraSure Technologies OraSure Technologies, Inc. ('OraSure' and 'OTI') transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit About DNA Genotek DNA Genotek, a subsidiary of OraSure Technologies, Inc., develops products that optimize ease of collection and provide superior samples and proven performance for those requiring high-quality biological samples. High-quality samples that are easily collected from target populations enable our customers to focus on translating their analysis and testing into significant worldwide advancements in health and science. DNA Genotek's products are marketed worldwide and support thousands of customers as they achieve breakthroughs in genomic research, in diagnostics laboratories, in the pharmaceutical industry, in livestock and animal genomics, and in personal genomics. For more information about DNA Genotek, visit Forward Looking Statements This press release contains certain 'forward-looking statements,' including with respect to products, product candidate development and regulatory authorizations and other matters. Forward-looking statements are based on current expectations of future events and are not guarantees of future performance or results. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from expectations and projections. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: uncertainty of commercial success; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; uncertainty of regulatory approvals; ability to comply with applicable regulatory requirements; uncertainty relating to patent protection and potential patent infringement claims; impact of competitors, competing products and technology changes and patents obtained by competitors; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; impact of negative economic conditions; changes in behavior and spending patterns of purchasers; trends toward healthcare cost containment; product efficacy or safety concerns resulting in product recalls or regulatory action; and changes to applicable laws and regulations. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements. * Stabilization is determined from a representative subset of plasma proteins. ** For research use only. Not for use in diagnostic procedures. Some DNA Genotek Inc. products are not available in all geographic regions. Customers must review the labels of sample collection devices and ensure compliance with their intended use. Investor Contact:Jason PlagmanVice President, Investor Relationsinvestorinfo@ Media Contact:Amy KochDirector, Corporate Communicationsmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-05-2025
- Business
- Yahoo
Top Penny Stocks To Watch In May 2025
As May 2025 unfolds, the U.S. stock market is experiencing a mix of optimism and caution, with indices like the S&P 500 and Nasdaq poised for their best monthly performance since 2023 amid ongoing trade discussions and economic data surprises. In this climate, penny stocks—often associated with smaller or newer companies—continue to capture investor interest due to their potential for growth at lower price points. Despite being considered a throwback term, these stocks can offer compelling opportunities when backed by strong financials and robust fundamentals. Name Share Price Market Cap Financial Health Rating Perfect (NYSE:PERF) $1.83 $186.38M ★★★★★★ WM Technology (NasdaqGS:MAPS) $1.05 $174.9M ★★★★★★ Puma Biotechnology (NasdaqGS:PBYI) $3.38 $167.28M ★★★★★★ Flexible Solutions International (NYSEAM:FSI) $4.31 $55.16M ★★★★★★ Imperial Petroleum (NasdaqCM:IMPP) $2.84 $98.08M ★★★★★★ Table Trac (OTCPK:TBTC) $4.77 $21.99M ★★★★★★ BAB (OTCPK:BABB) $0.848 $6.03M ★★★★★★ Lifetime Brands (NasdaqGS:LCUT) $3.47 $71.05M ★★★★★☆ New Horizon Aircraft (NasdaqCM:HOVR) $1.10 $30.73M ★★★★★★ Greenland Technologies Holding (NasdaqCM:GTEC) $2.02 $34.79M ★★★★★★ Click here to see the full list of 730 stocks from our US Penny Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: OraSure Technologies, Inc. is a company that develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices globally with a market cap of $207.20 million. Operations: OraSure Technologies generates revenue of $161.63 million from its Diagnostics and Molecular Solutions segment. Market Cap: $207.2M OraSure Technologies, with a market cap of US$207.20 million, is navigating the challenges typical for penny stocks. Despite being unprofitable, it has managed to reduce losses over the past five years and maintains a strong balance sheet with short-term assets of US$313.8 million exceeding both short-term and long-term liabilities. Recent developments include a collaboration with Targeted Genomics to expand consumer access to at-home celiac genetic testing and filing shelf registrations potentially raising up to US$315.78 million, which could provide financial flexibility but may also lead to shareholder dilution if executed fully. Navigate through the intricacies of OraSure Technologies with our comprehensive balance sheet health report here. Evaluate OraSure Technologies' prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Dingdong (Cayman) Limited operates as an e-commerce company in China, with a market cap of approximately $417.89 million. Operations: There are no reported revenue segments for Dingdong (Cayman) Limited. Market Cap: $417.89M Dingdong (Cayman) Limited, with a market cap of approximately US$417.89 million, has recently reported revenue growth, reaching CNY 5,479.04 million for Q1 2025 compared to the previous year. The company has become profitable over the past year and its operating cash flow covers debt well. Despite trading significantly below estimated fair value and having more cash than total debt, high Return on Equity is skewed by substantial debt levels. The management team and board are experienced, and the company announced a share repurchase program up to US$20 million funded from existing cash reserves until March 2026. Unlock comprehensive insights into our analysis of Dingdong (Cayman) stock in this financial health report. Examine Dingdong (Cayman)'s earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Nerdy, Inc. operates a platform for live online learning in the United States and has a market cap of approximately $307.55 million. Operations: The company's revenue is primarily generated from its tutoring segment, amounting to $184.10 million. Market Cap: $307.55M Nerdy, Inc., with a market cap of US$307.55 million, recently reported first-quarter 2025 sales of US$47.6 million, down from US$53.73 million the previous year, alongside a net loss increase to US$10.5 million. Despite being unprofitable and experiencing increased losses over five years, Nerdy has no debt and sufficient cash runway for more than a year based on current free cash flow trends. The company raised its full-year revenue guidance to between US$191.5 million and US$200 million due to first-quarter performance but faces challenges with significant insider selling in recent months. Click here to discover the nuances of Nerdy with our detailed analytical financial health report. Learn about Nerdy's future growth trajectory here. Unlock more gems! Our US Penny Stocks screener has unearthed 727 more companies for you to here to unveil our expertly curated list of 730 US Penny Stocks. Ready To Venture Into Other Investment Styles? These 19 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:OSUR NYSE:DDL and NYSE:NRDY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
